BeiGene Net Total Equity Issued/Repurchased 2014-2024 | ONC
BeiGene annual/quarterly net total equity issued/repurchased history and growth rate from 2014 to 2024. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- BeiGene net total equity issued/repurchased for the quarter ending September 30, 2024 was $0.037B, a 30.13% decline year-over-year.
- BeiGene net total equity issued/repurchased for the twelve months ending September 30, 2024 was $0.127B, a 23.27% decline year-over-year.
- BeiGene annual net total equity issued/repurchased for 2023 was $0.056B, a 18.63% increase from 2022.
- BeiGene annual net total equity issued/repurchased for 2022 was $0.047B, a 98.67% decline from 2021.
- BeiGene annual net total equity issued/repurchased for 2021 was $3.535B, a 18.26% decline from 2020.
BeiGene Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2023 |
$56 |
| 2022 |
$47 |
| 2021 |
$3,535 |
| 2020 |
$4,325 |
| 2019 |
$47 |
| 2018 |
$1,663 |
| 2017 |
$344 |
| 2016 |
$371 |
| 2015 |
$97 |
| 2014 |
$-0 |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
